HO
Hemogenyx Pharmaceuticals Plc
HOPHF · OTC
$2.33 +0.00% (+$0.00)
Market Cap £11.7M
P/E Ratio -
Div. Yield -
ROE 838.45%
Bulios Fair Price
$1.93
17.2% downside
Current Price
$2.33
Undervalued Fair Value Overvalued
According to Bulios Fair Price, HOPHF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/B 9.79x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Book val. growth 28.54%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 221.69%
ROE 838.45%
ROA 233.73%
Debt
28 /100
High Debt/Equity 1.68x
Current ratio 1.38x
Int. coverage -41.55x
Stability
41 /100
Moderate Beta 1.53x
EPS volatility 29.48%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about HOPHF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Vladislav Sandler
Employees
16
Headquarters
London